For the quarter ending 2025-12-31, OTLK had $594,339 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net (loss) income | -23,058,135 | -13,292,769 | -49,132,094 |
| Amortization | 30,074 | 29,737 | 87,315 |
| Warrant inducement expenses (note 10) | - | -334,940 | 33,856,814 |
| Stock-based compensation | 881,150 | 1,820,555 | 7,077,332 |
| Loss from change in fair value of promissory notes | 6,743,736 | 335,581 | 5,739,005 |
| Loss (gain) from change in fair value of warrant liability | 2,791,813 | -2,682,686 | -40,333,145 |
| Loss on equity method investment | -38,634 | -40,419 | -100,588 |
| Accounts receivable | -1,376,322 | -260,491 | 1,751,422 |
| Inventory | 119,660 | -788,312 | 4,126,716 |
| Prepaid expenses and other current assets | 439,855 | -1,840,783 | -6,171,166 |
| Other assets | - | 1 | 95,246 |
| Operating lease liabilities | -13,499 | -13,007 | -37,124 |
| Accounts payable | -2,873,739 | 30,255 | 1,635,794 |
| Accrued expenses | -295,952 | 354,702 | 1,355,493 |
| Income taxes payable | - | -1,554,629 | - |
| Net cash used in operating activities | -14,939,111 | -12,377,197 | -39,452,240 |
| Proceeds from debt | - | 0 | 33,100,000 |
| Repayment of debt | - | 2,325,581 | 33,817,005 |
| Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs | 14,931,536 | 8,085,009 | 17,311,389 |
| Proceeds from exercise of common stock warrants | 601,914 | 5,800,040 | 16,831,132 |
| Net cash provided by financing activities | 15,533,450 | 11,559,468 | 33,425,516 |
| Net increase (decrease) in cash and cash equivalents | 594,339 | -817,729 | -6,026,724 |
| Cash and cash equivalents at beginning of period | 8,083,085 | 14,927,538 | - |
| Cash and cash equivalents at end of period | 8,677,424 | 8,083,085 | - |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)